LONDON – The European Commission is laying plans for joint procurement of COVID-19 vaccines on behalf of all 27 EU member states, and is in discussions to agree on a harmonized approach to access and who gets vaccinated first.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Agios, Global Blood Therapeutics, Immune, Immunic, Immuron, Revive, Saniona.
Keeping you up to date on recent developments in cardiology, including: Stroke protection effects like night and day; Blood pressure meds help range of patients when taken as prescribed; Test IDs undetected blood clots in COVID-19 patients.
Regulatory snapshots, including global submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Chembio Diagnostics, Edwards, Genetron Health, Laminate Medical Technologies, Nuvaira, Surmodics.
Med-tech happenings, including deals and partnerships, grants, preclinical data and other news in brief: Arbor Vita, Cambridge University Hospitals, Cancer Research UK, Crh Medical, Flir, Geisinger, Gerpang Healthcare Group, Hypertension Diagnostics, Mainstay Medical, Makemedical, Nano-X Imaging, Promedica Bioelectronics, Rti Surgical, Siemens Healthineers, Spo Global, Xoran.
The biotech industry's rapid response to COVID-19, a pivot of global scope, is driving a broad array of approaches to tackling the infection. On Monday, the first day of BIO's virtual convention, the trade group gathered some of the effort's leading voices to take stock of how those efforts are shaping up. It put a spotlight on work underway at Athersys Inc., Regeneron Inc., SAB Biotherapeutics Inc., Takeda Pharmaceutical Co. Ltd. and Vir Biotechnology Inc.
When BIO 2019 closed its doors in Philadelphia last June, none of the delegates of the industry’s largest event would have predicted that the next meeting, scheduled for San Diego, would be canceled and the event would be transformed into a virtual version. In just a few months, the COVID-19 pandemic has decimated our normal way of life and, until effective therapeutics and vaccines become available, how we conduct the business of biotechnology will remain radically different. This will be one of the many themes explored during BIO Digital Week that kicked off today.
RSS
